RYSBEVI
"RYSBEVI" is a word mark owned by Sarepta Therapeutics, Inc., filed at the USPTO on June 24, 2025. It has been allowed and covers class 5 (Pharmaceuticals).
- Status
- Allowed
- Since June 24, 2026
- Filed
- June 24, 2025
- Registered
- Not yet
- Expires
- Not recorded
- Application no.
- 99249858
- Registration no.
- Not yet
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 1 class
Who owns RYSBEVI
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Sarepta Therapeutics, Inc.
SRPT · Cambridge, United States
Representative
Maury M Tepper, III
Tepper & Eyster, PLLC
What the mark covers
The products and services RYSBEVI is filed for, grouped by Nice class.
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations containing viral vectors for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations for gene therapy, gene editing, and genome editing for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Gene therapies, in the nature of pharmaceutical preparations, for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
What has happened so far
Steps recorded by the USPTO, newest first.
- Notice of approval of extension request e-mailed
- Sou extension 1 granted
- Sou extension 1 filed
- Sou teas extension received
- Noa e-mailed - sou required from applicant
- Official gazette publication confirmation e-mailed
- Published for opposition
- Notification of notice of publication e-mailed
- Approved for pub - principal register
- Teas/email correspondence entered
9 earlier steps on the official record.
About RYSBEVI
Who owns the trademark "RYSBEVI"?
The USPTO trademark "RYSBEVI" (application 99249858) is owned by Sarepta Therapeutics, Inc.
What is the status of "RYSBEVI"?
Its status at the USPTO is: allowed.
Get this data via the API
Everything on this page comes from the Signa API. Pull RYSBEVI and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2ae7-d977-70ca-b376-93e418dd92de
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2ae7-d977-70ca-b376-93e418dd92de",
"object": "trademark",
"mark_text": "RYSBEVI",
"status": {
"primary": "pending",
"stage": "allowed"
},
"office_code": "US",
"application_number": "99249858",
"filing_date": "2025-06-24",
"nice_classes": [
5
],
"owners": [
{
"name": "Sarepta Therapeutics, Inc.",
"entity_id": "ent_019ebbb7-51a3-7732-89ae-4e7311f24a9c"
}
]
}